Список литературы

1. N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016; 37(1).

2. N, Simonneau G. (eds). Updates in Pulmonary Hypertension Proceedings of the 5^th World Symposium on Pulmonary Hypertension. J Am Coll Cardiol. 2013; 62(25), Suppl D.

3. Чазова И.Е., Мартынюк Т.В. (ред.). Легочная гипертензия. М., 2015.

4. Choussat A., Fontan F., Besse P. Selection criteria for Fontan"s procedure. - In: Anderson R.H., Shineborne E.A. (eds). Pediatric cardiology. Edinburgh: Churchhill Livingstone; 1977: 559 - 570.

5. Hosein RB, Clarke AJ, McGuirk SP, Griselli M, Stumper O, De Giovanni JV et. al. Factors influencing early and late outcome following the Fontan procedure in the current era. The "Two Commandments"? Eur J Cardiothorac Surg. 2007; 31(3): 344 - 52.

6. Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ. 2011; (2): 286 - 298.

7. Dimopoulos K, Wort SJ, Gatzoulis MA. Pulmonary hypertension related to congenital heart disease: a call for action. Eur Heart J. 2014; 35(11): 691 - 700.

8. Nadas AS, Fyler DF. Pediatric cardiology. Philadelphia: WB Saunders; 1972: 684.

9. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease. Circulation. 1958; 18: 533 - 547.

10. Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010; 31(23): 2915 - 57.

11. D"Alto M, Mahadevan VS. Pulmonary arterial hypertension associated with congenital heart disease. Eur Respir Rev. 2012; 21(126): 328 - 37.

12. Gorbachevsky SV, Shmalts AA and Zaets SB. What Can Cause Pulmonary Vascular Disease in Functionally Single Ventricle? Anatomy & Physiology. 2016; 6(1): 1000e137. Available at: http://dx.doi.org/ 10.4172/2161-0940.1000e137.

13. Therrien J, Rambihar S, Newman B, Siminovitch K, Langleben D, Webb G et al. Eisenmenger syndrome and atrial septal defect: nature or nurture? Can J Cardiol. 2006; 22: 1133 - 1136.

14. Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J. 2014; 35(11): 716 - 24.

15. D"Alto M, Romeo E, Argiento P, Correra A, Santoro G, Gaio G et al. Hemodynamics of patients developing pulmonary arterial hypertension after shunt closure. Int J Cardiol. 2013; 168(4): 3797 - 801.

16. D'Alto M, Romeo E, Argiento P, Santoro G, Sarubbi B, Gaio G et al. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy. Heart Br Card Soc. 2010; 96: 1475 - 1479.

17. Post MC, Janssens S, Van de Werf F, Budts W. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J. 2004; 25: 1651 - 1656.

18. Бураковский В.И., Бухарин В.А., Плотникова Л.Р. Легочная гипертензия при врожденных пороках сердца. М.: Медицина; 1975.

19. Горбачевский С.В., Шмальц А.А. Гипертензионная сосудистая болезнь легких, ассоциированная с врожденными пороками сердца. В кн.: Детская кардиохирургия. Руководство для врачей. М., 2016: 833 - 850.

20. Горбачевский С.В., Шмальц А.А., Белкина М.В. Гренадеров М.А., Барышникова И.Ю., Пурсанов М.Г. и др. Алгоритм диагностики гипертензионной сосудистой болезни легких, ассоциированной с врожденными пороками сердца. Бюллетень НЦССХ им. А.Н. Бакулева РАМН Сердечно-сосудистые заболевания. 2015; 16(S3): 12.

21. Горбачевский С.В., Шмальц А.А., Белкина М.В., Гренадеров М.А., Рахмонов К.Х. Алгоритм определения показаний к хирургическому лечению врожденных пороков сердца с гипертензионной сосудистой болезнью легких. Бюллетень НЦССХ им. А.Н. Бакулева РАМН Сердечно-сосудистые заболевания. 2015; 16(S3): 12.

22. Lopes AA, Leary PW. Measurement, interpretation and use of hemodynamic parameters. Cardiol Young. 2009; 19(Suppl 1): 8 - 12.

23. Douwes JM, van Loon RL, Hoendermis ES, Vonk-Noordegraaf A, Roofthooft MT, Talsma MD et al. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. Eur Heart J. 2011; 32(24): 3137 - 46.

24. Nakanishi T. Pulmonary arterial hypertension associated with congenital heart disease. Personal perspectives. Int Heart J. 2015; 56. Suppl: S1 - 3. doi: 10.1536/ihj.15-064.

25. Moller JH, Patton C, Varco RL, Lillehei CW. Late results (30 to 35 years) after operative closure of isolated ventricular septal defect from 1954 to 1960. Am J Cardiol 1991; 68: 1491 - 1497.

26. Galie` N, Manes A, Palazzini M, Negro L, Marinelli A, Gambetti S et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. Drugs. 2008; 68: 1049 - 1066.

27. Kaemmerer H, Niwa K, Oechslin E, Ewert P, Webb GD, Hess J. Pulmonary Arterial Hypertension in Congenital Heart Disease: Eisenmenger"s Syndrome - A Global Perspective. Bremen: UNI-MED, 2013

28. Broberg CS, Ujita M, Prasad S, Li W, Rubens M, Bax BE et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol. 2007; 50: 634 - 642.

29. Sandoval J, Aguirre JS, Pulido T, Martinez-Guerra ML, Santos E, Alvarado P et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med. 2001; 164: 1682 - 1687.

30. Diller GP, Lammers AE, Haworth SG, Dimopoulos K, Derrick G, Bonhoeffer P et al. A modelling study of atrial septostomy for pulmonary arterial hypertension, and its effect on the state of tissue oxygenation and systemic blood flow. Cardiol Young. 2010; 20: 25 - 32.

31. Broberg CS, Bax BE, Okonko DO, Rampling MW, Bayne S, Harries C et al. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. J Am Coll Cardiol. 2006; 48: 356 - 365.

32. Rhodes CJ, Howard LS, Busbridge M, Ashby D, Kondili E, Gibbs JS et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol. 2011; 58: 300 - 309.

33. Galie` N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006; 114: 48 - 54.

34. Gatzoulis MA, Beghetti M, Galie` N, Granton J, Berger RM, Lauer A et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. 2007; 127: 27 - 32.

35. Zuckerman WA, Leaderer D, Rowan CA, Mituniewicz JD, Rosenzweig EB. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. J Am Coll Cardiol. 2011; 107: 1381 - 1385.

36. Mukhopadhyay S, Sharma M, Ramakrishnan S, Yusuf J, Gupta MD, Bhamri N et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation. 2006; 114: 1807 - 1810.

37. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary

38. Tay EL, Papaphylactou M, Diller GP, Alonso-Gonzalez R, Inuzuka R, Giannakoulas G et al. Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy. Int J Cardiol 2011; 149: 372 - 376.

39. Zhang ZN, Jiang X, Zhang R, Li XL, Wu BX, Zhao QH et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart 2011; 97: 1876 - 1881.

40. Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007; 120: 301 - 305.

41. Rosenkranz S, Ghofrani HA, Beghetti M, Ivy D, Frey R, Fritsch A et al. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart. 2015; 101(22): 1792 - 9.

42. Pulido T, Adzerikho I, Channick RN, Delcroix M, N, Ghofrani HA et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369(9): 809 - 18.

43. N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353(20): 2148 - 57.

44. Galie` N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008; 371: 2093 - 2100.

45. Hebert A, Mikkelsen UR, Thilen U, Idorn L, Jensen AS, Nagy E et al. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study. Circulation. 2014; 130(23): 2021 - 30.

46. Goldberg DJ, French B, McBride MG, Marino BS, Mirarchi N, Hanna BD et al. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation. 2011; 123(11): 1185 - 93.

47. Shang XK, Lu R, Zhang X, Zhang CD, Xiao SN, Liu M J et al. Efficacy of Bosentan inpatients after Fontan procedures: a double-blind, randomized controlled trial. J Huazhong Univ Sci Technolog Med Sci. 2016; 36(4): 534 - 40.

48. Mori H, Park IS, Yamagishi H, Nakamura M, Ishikawa S, Takigiku K et al. Sildenafil reduces pulmonary vascular resistance in single ventricular physiology. Int J Cardiol. 2016; 221: 122 - 7.

49. Hirono K, Yoshimura N, Taguchi M, Watanabe K, Nakamura T, Ichida F et al. Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery. J. Thorac. Cardiovasc. Surg. 2010; 140: 346 - 351.

50. Inuzuka R, Tatebe S, Wakiguchi S, Nakajima H, Ohtsu H, Dimopoulos K et al. B-type natriuretic peptide at the early stage of univentricular circulation reflects inadequate adaptation to volume overload. Int J Cardiol. 2012; 159(2): 88 - 93.

51. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, L. et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010; 31: 1124 - 1131.

52. D'Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. 2012; 155: 378 - 82.

53. Montani D, Savale L, Natali D, X, Herve P, Garcia G et al. Long-term response to calcium-channel blockers in nonidiopathic pulmonary arterial hypertension. Eur Heart J. 2010; 31: 1898 - 1907.

54. Рыбка М.М., Хинчагов Д.Я., Мумладзе К.В., Лобачева Г.В., Ведерникова Л.В. Под ред. Л.А. Бокерия. Протоколы анестезиологического обеспечения кардиохирургических операций, выполняемых у новорожденных и детей. Методические рекомендации. М.: НЦССХ им. А.Н. Бакулева РАМН; 2014.

55. Рыбка М.М., Хинчагов Д.Я. Под ред. Л.А. Бокерия. Протоколы анестезиологического обеспечения кардиохирургических операций, выполняемых при ишемической болезни сердца, патологии клапанного аппарата, нарушениях ритма, гипертрофической кардиомиопатии, аневризмах восходящего отдела аорты у пациентов различных возрастных групп. Методические рекомендации. М.: НЦССХ им. А.Н. Бакулева РАМН; 2015.

56. Рыбка М.М., Хинчагов Д.Я., Мумладзе К.В., Никулкина Е.С. Под ред. Л.А. Бокерия. Протоколы анестезиологического обеспечения рентгенэндоваскулярных и диагностических процедур, выполняемых у кардиохирургических пациентов различных возрастных групп. Методические рекомендации. М.: НЦССХ им. А.Н. Бакулева РАМН; 2018

57. Xu Z, Zhu L, Liu X, Gong X, Gattrell W, Liu J. Iloprost for children with pulmonary hypertension after surgery to correct congenital heart disease. Pediatr Pulmonol. 2015; 50(6): 588 - 95.

58. Alehan D, I, Sahin M, Ozkutlu S, Ozer S, T. Long-term inhaled iloprost use in children with pulmonary arterial hypertension. Cardiol Young. 2012; 22(4): 396 - 403.

59. Sung KW, Jeon YB, Kim NY, Park KY, Park CH, Choi CH et al. The effects of perioperative inhaled iloprost on pulmonary hypertension with congenital heart disease. Cardiology. 2013; 126(4): 224 - 9.

60. A, Torrent-Vernetta A, de Mir Messa I, Rovira Amigo S, Gran F, Gartner S et al. Use of inhaled iloprost in children with pulmonary hypertension. Pediatr Pulmonol. 2015; 50(4): 370 - 9.

61. Limsuwan A, Wanitkul S, Khosithset A, Attanavanich S, Samankatiwat P. Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. Int J Cardiol. 2008; 129(3): 333 - 8.

62. M, Scholz S, Maxeiner H, Brenck F, Valeske K, Thul J et al. Efficacy of inhaled iloprost in the management of pulmonary hypertension after cardiopulmonary bypass in infants undergoing congenital heart surgery. A case series of 31 patients. HSR Proc Intensive Care Cardiovasc Anesth. 2011; 3(2): 123 - 30.

63. Beghetti M, Haworth SG, Bonnet D, Barst RJ, Acar P, Fraisse A, Ivy DD et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol. 2009; 68: 948 - 55.

64. Berger RM, Haworth SG, Bonnet D, Dulac Y, Fraisse A, N et al. FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric Formulation of bosentan in pulmonary arterial hypertension. Int J Cardiol. 2016; 202: 52 - 8.

65. M, Sidharta PN, Dingemanse J. Bosentan Pharmacokinetics in Pediatric Patients with Pulmonary Arterial Hypertension: Comparison of Dried Blood Spot and Plasma Analysis. Pharmacology. 2016; 98(3 - 4): 111 - 4.

66. Brun H, Thaulow E, Fredriksen PM, Holmstrom H. Treatment of patients with Eisenmenger's syndrome with Bosentan. Cardiol Young. 2007; 17(3): 288 - 94.

67. Ivy DD, Doran A, Claussen L, Bingaman D, Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol. 2004; 93(7): 943 - 6.

68. Gilbert N, Luther YC, Miera O, Nagdyman N, Ewert P, Berger F et al. Initial experience with bosentan (Tracleer) as treatment for pulmonary arterial hypertension (PAH) due to congenital heart disease in infants and young children. Z Kardiol. 2005; 94(9): 570 - 4.

69. Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. Heart. 2005; 91(11): 1447 - 52.

70. van Loon RL, Hoendermis ES, Duffels MG, Vonk-Noordegraaf A, Mulder BJ, Hillege HL et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J. 2007; 154(4): 776 - 82.

71. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart. 2006; 92(5): 664 - 70.

72. Simpson CM, Penny DJ, Cochrane AD, Davis AM, Rose ML, Wilson SE et al. Preliminary experience with bosentan as initial therapy in childhood idiopathic pulmonary arterial hypertension. J Heart Lung Transplant. 2006; 25(4): 469 - 73.

73. Ivy DD, Rosenzweig EB, JC, Brand M, Rosenberg D, Barst RJ. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol. 2010; 106(9): 1332 - 8.

74. Hislop AA, Moledina S, Foster H, Schulze-Neick I, Haworth SG. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J. 2011; 38(1): 70 - 7.

75. Taguchi M, Ichida F, Hirono K, Miyawaki T, Yoshimura N, Nakamura T et al. Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. Drug Metab Pharmacokinet. 2011; 26(3): 280 - 7.

76. Rhodes J, Ubeda-Tikkanen A, Clair M, Fernandes SM, Graham DA, Milliren CE et al. Effect of inhaled iloprost on the exercise function of Fontan patients: a demonstration of concept. Int J Cardiol. 2013; 168(3): 2435 - 40.